![Martin Christiaan de Groot](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Martin Christiaan de Groot worked as the Chief Financial Officer at P&I Personal & Informatik AG from 2013 to 2015.
He also worked as the Chief Financial Officer at Xeltis AG.
Former positions of Martin Christiaan de Groot
Companies | Position | End |
---|---|---|
P&I PERSONAL & INFORMATIK AG | Director of Finance/CFO | 2015-09-30 |
Xeltis AG
![]() Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Director of Finance/CFO | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
P&I Personal & Informatik AG
![]() P&I Personal & Informatik AG Packaged SoftwareTechnology Services P&I Personal & Informatik AG provides integrated software solutions and services for human resources management. It consists of four product lines including P&I LOGA, P&I PLUS, P&I TIME, and P&I SMART. The company was founded in 1968 and is headquartered in Wiesbaden, Germany. | Technology Services |
Xeltis AG
![]() Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Martin Christiaan de Groot